Gastrointestinal Cancer News

The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.

Indications for which cancer drugs receive accelerated approval often remain on drug labeling after confirmatory trials show no improvement in the primary efficacy endpoint, results of a retrospective, observational study showed.

Patients with solid tumor cancers sustained similar COVID-19 antibody levels as individuals without cancer 6 months after the second dose of the mRNA COVID-19 vaccine, according to study results published in Cancer Discovery.

Amid lockdowns, many countries implemented a suspension of routine surveillance for colorectal cancer, resulting in fewer diagnoses in older patients with more complications, according to a presentation during UEG Week Virtual.

Artificial intelligence-based computer-aided polyp detection decreased adenoma miss rate and increased first-pass adenoma per colonoscopy detection, according to research published in Clinical Gastroenterology and Hepatology.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The FDA approved cetuximab in combination with encorafenib for treatment of certain patients with colorectal cancer.

The FDA granted fast track designation to acelarin for treatment of biliary tract cancer.

Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.